

Richard PÄjttter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2731691/publications.pdf>

Version: 2024-02-01

330
papers

23,446
citations

8181

76
h-index

10158

140
g-index

344
all docs

344
docs citations

344
times ranked

9761
citing authors

#	ARTICLE	IF	CITATIONS
1	Exclusive 3D-brachytherapy as a good option for stage-I inoperable endometrial cancer: a retrospective analysis in the gynaecological cancer GEC-ESTRO Working Group. Clinical and Translational Oncology, 2022, 24, 254-265.	2.4	7
2	Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 400-413.	0.8	20
3	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. International Journal of Radiation Oncology Biology Physics, 2022, 112, 681-693.	0.8	14
4	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1177-1189.	0.8	6
5	Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. Radiotherapy and Oncology, 2022, 168, 8-15.	0.6	11
6	Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 379-389.	0.8	7
7	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 161-173.	0.8	16
8	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 688-700.	0.8	31
9	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 300-308.	0.6	23
10	Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. Radiotherapy and Oncology, 2021, 155, 151-159.	0.6	13
11	Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: a prospective cohort study covering modern treatment techniques. Strahlentherapie Und Onkologie, 2021, 197, 505-519.	2.0	11
12	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncology, The, 2021, 22, 538-547.	10.7	268
13	Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. Radiotherapy and Oncology, 2021, 157, 24-31.	0.6	6
14	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 312-320.	0.6	33
15	Response to Yuce Sari et al.. Radiotherapy and Oncology, 2021, 158, 323-324.	0.6	0
16	Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, 168-177.	0.8	24
17	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 163, 150-158.	0.6	12
18	Quantitative and qualitative application of clinical drawings for image-guided brachytherapy in cervical cancer patients. Journal of Contemporary Brachytherapy, 2021, 13, 512-518.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidityâ€”Applied in the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2020, 106, 300-309.	0.8	22
20	Recommendations from gynaecological (GYN) GEC-ESTRO working group â€” ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiotherapy and Oncology, 2020, 145, 36-44.	0.6	32
21	Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer. Strahlentherapie Und Onkologie, 2020, 196, 983-992.	2.0	7
22	Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. Seminars in Radiation Oncology, 2020, 30, 311-327.	2.2	32
23	Education and training for image-guided adaptive brachytherapy for cervix cancerâ€”The (GEC)-ESTRO/EMBRACE perspective. Brachytherapy, 2020, 19, 827-836.	0.5	22
24	Image guidance in radiation therapy for better cure of cancer. Molecular Oncology, 2020, 14, 1470-1491.	4.6	63
25	Dose planning variations related to delineation variations in MRI-guided brachytherapy for locally advanced cervical cancer. Brachytherapy, 2020, 19, 146-153.	0.5	12
26	MRI-based contouring of functional sub-structures of the lower urinary tract in gynaecological radiotherapy. Radiotherapy and Oncology, 2020, 145, 117-124.	0.6	13
27	Ring Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2020, 106, 1052-1062.	0.8	51
28	Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer. Brachytherapy, 2020, 19, 837-849.	0.5	6
29	Attitude Towards End of Life Communication of Austrian Medical Students. Journal of Cancer Education, 2019, 34, 743-748.	1.3	2
30	Uveal Melanoma: Stereotactic Radiation Therapy. , 2019, , 233-240.		0
31	Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. International Journal of Radiation Oncology Biology Physics, 2019, 105, 957-967.	0.8	17
32	Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome. Radiotherapy and Oncology, 2019, 141, 123-129.	0.6	35
33	Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. Radiotherapy and Oncology, 2019, 133, 149-155.	0.6	12
34	Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 895-902.	0.8	62
35	Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiotherapy and Oncology, 2019, 134, 185-190.	0.6	41
36	Image-guided Adaptive Radiotherapy in Cervical Cancer. Seminars in Radiation Oncology, 2019, 29, 284-298.	2.2	47

#	ARTICLE	IF	CITATIONS
37	Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II. International Journal of Radiation Oncology Biology Physics, 2019, 104, 885-894.	0.8	39
38	The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy. Strahlentherapie Und Onkologie, 2019, 195, 430-440.	2.0	9
39	Management of Nodal Disease in Advanced Cervical Cancer. Seminars in Radiation Oncology, 2019, 29, 158-165.	2.2	34
40	Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. International Journal of Radiation Oncology Biology Physics, 2019, 103, 887-894.	0.8	39
41	Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 834-844.	10.7	102
42	Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study. Radiotherapy and Oncology, 2018, 127, 440-448.	0.6	30
43	Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. Radiotherapy and Oncology, 2018, 127, 449-455.	0.6	23
44	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clinical and Translational Radiation Oncology, 2018, 9, 48-60.	1.7	415
45	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiotherapy and Oncology, 2018, 127, 404-416.	0.6	241
46	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer, 2018, 28, 641-655.	2.5	336
47	Ä–GRO survey on radiotherapy capacity in Austria. Strahlentherapie Und Onkologie, 2018, 194, 284-292.	2.0	2
48	Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Molecular Imaging and Biology, 2018, 20, 160-169.	2.6	16
49	Image guided adaptive external beam radiation therapy for cervix cancer: Evaluation of a clinically implemented plan-of-the-day technique. Zeitschrift Fur Medizinische Physik, 2018, 28, 184-195.	1.5	28
50	Postoperative radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2018, 194, 23-30.	2.0	10
51	Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy. Radiotherapy and Oncology, 2018, 129, 567-574.	0.6	39
52	Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiotherapy and Oncology, 2018, 127, 423-430.	0.6	54
53	Early ultrasonographic tumor regression after linear accelerator stereotactic fractionated photon radiotherapy of choroidal melanoma as a predictor for metastatic spread. Radiotherapy and Oncology, 2018, 127, 385-391.	0.6	2
54	Union of light ion therapy centers in Europe (ULICE EC FP7) – Objectives and achievements of joint research activities. Radiotherapy and Oncology, 2018, 128, 83-100.	0.6	6

#	ARTICLE	IF	CITATIONS
55	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 919-936.	2.8	127
56	Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 431-439.	0.6	69
57	Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 259-268.	10.7	220
58	Reply to the Letter to the Editor by H. Yamazaki et al.. <i>Radiotherapy and Oncology</i> , 2017, 123, 170-171.	0.6	0
59	Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1056-1065.	2.0	20
60	Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 420-425.	0.6	25
61	Vienna Summer School on Oncology: how to teach clinical decision making in a multidisciplinary environment. <i>BMC Medical Education</i> , 2017, 17, 100.	2.4	12
62	Advancements in brachytherapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 15-25.	13.7	67
63	Inflatable multichannel rectal applicator for adaptive image-guided endoluminal high-dose-rate rectal brachytherapy: design, dosimetric characteristics, and first clinical experiences. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 359-363.	0.9	3
64	Total reference air kerma can accurately predict isodose surface volumes in cervix cancer brachytherapy. A multicenter study. <i>Brachytherapy</i> , 2017, 16, 1184-1191.	0.5	12
65	Particle Therapy or Brachytherapy?., 2017, , 361-368.		0
66	Impact of heterogeneity-corrected dose calculation using a grid-based Boltzmann solver on breast and cervix cancer brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2016, 2, 143-149.	0.9	22
67	Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 441-446.	0.6	252
68	Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 120, 412-419.	0.6	198
69	Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 120, 434-440.	0.6	236
70	Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. <i>Radiotherapy and Oncology</i> , 2016, 120, 428-433.	0.6	527
71	A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with ICABT in a prospective multicentric trial (EMBRACE). <i>Radiotherapy and Oncology</i> , 2016, 120, 404-411.	0.6	42
72	Can reduction of uncertainties in cervix cancer brachytherapy potentially improve clinical outcome?. <i>Radiotherapy and Oncology</i> , 2016, 120, 390-396.	0.6	20

#	ARTICLE	IF	CITATIONS
73	Combining transrectal ultrasound and CT for image-guided adaptive brachytherapy of cervical cancer: Proof of concept. Brachytherapy, 2016, 15, 839-844.	0.5	46
74	Image Guided Brachytherapy in Cervical Cancer: A Comparison between Intracavitary and Combined Intracavitary/Interstitial Brachytherapy in Regard to Doses to HR CTV, OARs and Late Morbidity - Early Results from the Embrace Study in 999 Patients. Brachytherapy, 2016, 15, S21.	0.5	14
75	Image Guided Adaptive Brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome. Radiotherapy and Oncology, 2016, 120, 365-369.	0.6	50
76	Impact of organ shape variations on margin concepts for cervix cancer ART. Radiotherapy and Oncology, 2016, 120, 526-531.	0.6	23
77	GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiotherapy and Oncology, 2016, 120, 119-123.	0.6	90
78	Vaginal dose de-escalation in image guided adaptive brachytherapy for locally advanced cervical cancer. Radiotherapy and Oncology, 2016, 120, 480-485.	0.6	33
79	Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients. Radiotherapy and Oncology, 2016, 120, 420-427.	0.6	28
80	Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiotherapy and Oncology, 2016, 118, 160-166.	0.6	153
81	In response to the letter to the editor from Sylvia van Dyk et al. regarding our editorial "High-tech image-guided therapy vs. low-tech, simple, cheap gynecologic brachytherapy". Brachytherapy, 2016, 15, 207.	0.5	0
82	Value of Magnetic Resonance Imaging Without or With Applicator in Place for Target Definition in Cervix Cancer Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2016, 94, 588-597.	0.8	34
83	Transrectal ultrasound for image-guided adaptive brachytherapy in cervix cancer "An alternative to MRI for target definition?". Radiotherapy and Oncology, 2016, 120, 467-472.	0.6	48
84	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1088-1098.	0.8	77
85	5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. The, 2016, 387, 229-238.	13.7	578
86	Original paper Improved source path localisation in ring applicators and the clinical impact for gynecological brachytherapy. Journal of Contemporary Brachytherapy, 2015, 3, 239-243.	0.9	7
87	High-tech image-guided therapy versus low-tech, simple, cheap gynecologic brachytherapy. Brachytherapy, 2015, 14, 910-912.	0.5	7
88	Establishing a Global Radiation Oncology Collaboration in Education (GRaCE): Objectives and priorities. Radiotherapy and Oncology, 2015, 117, 188-192.	0.6	15
89	Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiotherapy and Oncology, 2015, 117, 509-514.	0.6	25
90	Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncology, The, 2015, 16, e93-e100.	10.7	423

#	ARTICLE	IF	CITATIONS
91	Use of bladder dose points for assessment of the spatial dose distribution in the posterior bladder wall in cervical cancer brachytherapy and the impact of applicator position. <i>Brachytherapy</i> , 2015, 14, 252-259.	0.5	15
92	Information preferences regarding cure rates and prognosis of Austrian patients with advanced lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 549-556.	2.0	13
93	Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE). <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 788-796.	0.8	34
94	Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008. <i>Acta Oncologica</i> , 2015, 54, 1551-1557.	1.8	14
95	Quality assurance in MR image guided adaptive brachytherapy for cervical cancer: Final results of the EMBRACE study dummy run. <i>Radiotherapy and Oncology</i> , 2015, 117, 548-554.	0.6	37
96	Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery – A mono-institutional prospective study. <i>Gynecologic Oncology</i> , 2015, 136, 415-423.	1.4	46
97	In Reply to Whitley et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 469-470.	0.8	0
98	Four years with FALCON – An ESTRO educational project: Achievements and perspectives. <i>Radiotherapy and Oncology</i> , 2014, 112, 145-149.	0.6	44
99	Curative Radiation Therapy for Locally Advanced Cervical Cancer: Brachytherapy Is NOT Optional. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 537-539.	0.8	165
100	Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 88-95.	0.8	106
101	Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 260-267.	0.8	68
102	Adaptive image guided brachytherapy for cervical cancer: A combined MRI/CT-planning technique with MRI only at first fraction. <i>Radiotherapy and Oncology</i> , 2013, 107, 75-81.	0.6	85
103	Single line source with and without vaginal loading and the impact on target coverage and organ at risk doses for cervix cancer Stages IB, II, and IIIB: Treatment planning simulation in patients treated with MRI-guided adaptive brachytherapy in a multicentre study (EMBRACE). <i>Brachytherapy</i> , 2013, 12, 317-323.	0.5	16
104	Dose-response of critical structures in the posterior eye segment to hypofractionated stereotactic photon radiotherapy of choroidal melanoma. <i>Radiotherapy and Oncology</i> , 2013, 108, 348-353.	0.6	10
105	High-risk clinical target volume delineation in CT-guided cervical cancer brachytherapy: Impact of information from FIGO stage with or without systematic inclusion of 3D documentation of clinical gynecological examination. <i>Acta Oncologica</i> , 2013, 52, 1345-1352.	1.8	54
106	Feasibility of transrectal ultrasonography for assessment of cervical cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 123-128.	2.0	50
107	A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 20-25.	0.6	86
108	Uncertainties in image guided adaptive cervix cancer brachytherapy: Impact on planning and prescription. <i>Radiotherapy and Oncology</i> , 2013, 107, 1-5.	0.6	74

#	ARTICLE	IF	CITATIONS
109	Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 99-105.	0.6	47
110	Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: Assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance. <i>Radiotherapy and Oncology</i> , 2013, 107, 26-31.	0.6	45
111	Dose to the non-involved uterine corpus with MRI guided brachytherapy in locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2013, 107, 93-98.	0.6	13
112	In Reply A. Sharma et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 288-289.	0.8	0
113	Uncertainties of target volume delineation in MRI guided adaptive brachytherapy of cervix cancer: A multi-institutional study. <i>Radiotherapy and Oncology</i> , 2013, 107, 6-12.	0.6	80
114	Dosimetric impact of interobserver variability in MRI-based delineation for cervical cancer brachytherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 13-19.	0.6	87
115	Magnetic resonance imaging for assessment of parametrial tumour spread and regression patterns in adaptive cervix cancer radiotherapy. <i>Acta Oncologica</i> , 2013, 52, 1384-1390.	1.8	32
116	Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95. <i>Journal of Clinical Oncology</i> , 2013, 31, 1562-1568.	1.6	127
117	Dose Effect Relationship for Late Side Effects of the Rectum and Urinary Bladder in Magnetic Resonance Image-Guided Adaptive Cervix Cancer Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 653-657.	0.8	194
118	Cone-Beam CT-Based Delineation of Stereotactic Lung Targets: The Influence of Image Modality and Target Size on Interobserver Variability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e265-e272.	0.8	39
119	Treatment of Locally Advanced Vaginal Cancer With Radiochemotherapy and Magnetic Resonance Image-Guided Adaptive Brachytherapy: Dose-Volume Parameters and First Clinical Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1880-1888.	0.8	59
120	Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: Alternative to mastectomy? Results from a prospective trial. <i>Radiotherapy and Oncology</i> , 2012, 102, 96-101.	0.6	82
121	Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. <i>Radiotherapy and Oncology</i> , 2012, 103, 113-122.	0.6	342
122	Comparison between external beam radiotherapy (70Gy/74Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2012, 103, 223-227.	0.6	17
123	The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology. <i>Radiotherapy and Oncology</i> , 2012, 103, 103-108.	0.6	81
124	Competencies in radiation oncology: A new approach for education and training of professionals for Radiotherapy and Oncology in Europe. <i>Radiotherapy and Oncology</i> , 2012, 103, 1-4.	0.6	33
125	Late gastrointestinal and urogenital side-effects after radiotherapy – Incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2012, 104, 114-118.	0.6	42
126	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. <i>BMC Cancer</i> , 2012, 12, 137.	2.6	46

#	ARTICLE	IF	CITATIONS
127	Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. Radiation Oncology, 2012, 7, 115.	2.7	11
128	Comparison of seed brachytherapy or external beam radiotherapy (70ÂGy or 74ÂGy) in 919 low-risk prostate cancer patients. Strahlentherapie Und Onkologie, 2012, 188, 305-310.	2.0	15
129	Adaptive Contouring of the Target Volume and Organs at Risk. , 2011, , 99-118.		6
130	Clinical Aspects of Treatment Planning. , 2011, , 119-130.		3
131	Feasibility of CBCT-based target and normal structure delineation in prostate cancer radiotherapy: Multi-observer and image multi-modality study. Radiotherapy and Oncology, 2011, 98, 154-161.	0.6	78
132	Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiotherapy and Oncology, 2011, 100, 116-123.	0.6	649
133	Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: A comparison of spatial dose distribution within a matched-pair analysis. Radiotherapy and Oncology, 2011, 100, 468-472.	0.6	54
134	Image guided, adaptive, accelerated, high dose brachytherapy as model for advanced small volume radiotherapy. Radiotherapy and Oncology, 2011, 100, 333-343.	0.6	31
135	Healing of Late Endoscopic Changes in the Rectum between 12 and 65 Months after External Beam Radiotherapy. Strahlentherapie Und Onkologie, 2011, 187, 202-205.	2.0	29
136	Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlentherapie Und Onkologie, 2011, 187, 373-377.	2.0	24
137	Doseâ€Volume Histogram Parameters and Late Side Effects in Magnetic Resonance Imageâ€Guided Adaptive Cervical Cancer Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 356-362.	0.8	164
138	Accelerated Partial Breast Irradiation: 5-Year Results of the German-Austrian Multicenter Phase II Trial Using Interstitial Multicatheter Brachytherapy Alone After Breast-Conserving Surgery. International Journal of Radiation Oncology Biology Physics, 2011, 80, 17-24.	0.8	116
139	Accelerated Partial Breast Irradiation With Interstitial Implants: Risk Factors Associated With Increased Local Recurrence. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1458-1463.	0.8	33
140	Parametrial Boost Using Midline Shielding Results in an Unpredictable Dose to Tumor and Organs at Risk in Combined External Beam Radiotherapy and Brachytherapy for Locally Advanced Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1572-1579.	0.8	52
141	In Response to Dr. Wei and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 81, 315-316.	0.8	0
142	Austria: Medical University of Vienna, Vienna. , 2011, , 173-179.		0
143	Outcomes Related to the Disease and the Use of 3D-Based External Beam Radiation and Image-Guided Brachytherapy. , 2011, , 263-282.		0
144	Morbidity Related to the Use of 3D-Based External Beam Radiation and Image-Guided Brachytherapy. , 2011, , 283-297.		0

#	ARTICLE	IF	CITATIONS
145	Betulinic Acid a Radiosensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines. Strahlentherapie Und Onkologie, 2010, 186, 143-148.	2.0	41
146	Investigations on Parotid Gland Recovery after IMRT in Head and Neck Tumor Patients. Strahlentherapie Und Onkologie, 2010, 186, 665-671.	2.0	26
147	Vienna International Summer School on Experimental and Clinical Oncology for Medical Students: An Austrian Cancer Education Project. Journal of Cancer Education, 2010, 25, 51-54.	1.3	10
148	Adaptive Management of Cervical Cancer Radiotherapy. Seminars in Radiation Oncology, 2010, 20, 121-129.	2.2	104
149	New Vienna Applicator Design for Distal Parametrial Disease in Cervical Cancer. Brachytherapy, 2010, 9, S51-S52.	0.5	11
150	Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatric Blood and Cancer, 2010, 55, 1145-1152.	1.5	150
151	Physics Contributions Original article A detailed dosimetric comparison between manual and inverse plans in HDR intracavitary/interstitial cervical cancer brachytherapy. Journal of Contemporary Brachytherapy, 2010, 4, 163-170.	0.9	24
152	Variation of treatment planning parameters (D90 HR-CTV, D2cc for OAR) for cervical cancer tandem ring brachytherapy in a multicentre setting: Comparison of standard planning and 3D image guided optimisation based on a joint protocol for doseâ€‘volume constraints. Radiotherapy and Oncology, 2010, 94, 339-345.	0.6	56
153	Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy?. Radiotherapy and Oncology, 2010, 94, 324-327.	0.6	13
154	Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Europ��en de Curieth��rapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiotherapy and Oncology, 2010, 94, 264-273.	0.6	546
155	Dose volume parameter D2cc does not correlate with vaginal side effects in individual patients with cervical cancer treated within a defined treatment protocol with very high brachytherapy doses. Radiotherapy and Oncology, 2010, 97, 76-79.	0.6	49
156	Comparison of DVH parameters and loading patterns of standard loading, manual and inverse optimization for intracavitary brachytherapy on a subset of tandem/ovoid cases. Radiotherapy and Oncology, 2010, 97, 501-506.	0.6	36
157	PTV margins should not be used to compensate for uncertainties in 3D image guided intracavitary brachytherapy. Radiotherapy and Oncology, 2010, 97, 495-500.	0.6	46
158	Patterns of care for brachytherapy in Europe: Updated results. Radiotherapy and Oncology, 2010, 97, 514-520.	0.6	81
159	Evaluating repetitive¹⁸F-fluoroazomycin-arabinoside (¹⁸FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol��gica, 2010, 49, 941-947.	1.8	68
160	Beta endovascular brachytherapy using CO2-filled centering catheter for treatment of recurrent superficial femoropopliteal artery disease. Cardiovascular Revascularization Medicine, 2009, 10, 162-165.	0.8	10
161	Doseâ€‘Volume Histogram Parameters and Local Tumor Control in Magnetic Resonance Imageâ€‘Guided Cervical Cancer Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 56-63.	0.8	207
162	MRI Assessment of Cervical Cancer for Adaptive Radiotherapy. Strahlentherapie Und Onkologie, 2009, 185, 282-287.	2.0	64

#	ARTICLE	IF	CITATIONS
163	The Cyclooxygenase-2 Inhibitor Nimesulide, a Nonsteroidal Analgesic, Decreases the Effect of Radiation Therapy in Head-and-Neck Cancer Cells. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 310-317.	2.0	13
164	Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 94-100.	2.0	46
165	Moderate Dose Escalation in Three-Dimensional Conformal Localized Prostate Cancer Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 438-445.	2.0	27
166	Treatment of Vascular Soft Tissue Sarcomas With Razoxane, Vindesine, and Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 187-191.	0.8	10
167	Critical discussion of different dose–volume parameters for rectum and urethra in prostate brachytherapy. <i>Brachytherapy</i> , 2009, 8, 353-360.	0.5	7
168	Long-term results of the German-Austrian phase II study – accelerated partial breast irradiation using multicatheter brachytherapy for early breast cancer. <i>Brachytherapy</i> , 2009, 8, 107.	0.5	8
169	Inter-observer comparison of target delineation for MRI-assisted cervical cancer brachytherapy: Application of the GYN GEC-ESTRO recommendations. <i>Radiotherapy and Oncology</i> , 2009, 91, 166-172.	0.6	93
170	Correlation of dose–volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy. <i>Radiotherapy and Oncology</i> , 2009, 91, 173-180.	0.6	107
171	Image-guided brachytherapy sets benchmarks in advanced radiotherapy. <i>Radiotherapy and Oncology</i> , 2009, 91, 141-146.	0.6	16
172	Dose–effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. <i>Radiotherapy and Oncology</i> , 2009, 93, 311-315.	0.6	225
173	Direct reconstruction of the Vienna applicator on MR images. <i>Radiotherapy and Oncology</i> , 2009, 93, 347-351.	0.6	48
174	New inverse planning technology for image-guided cervical cancer brachytherapy: Description and evaluation within a clinical frame. <i>Radiotherapy and Oncology</i> , 2009, 93, 331-340.	0.6	43
175	Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 163-167.	2.5	20
176	Assessment of Improved Organ at Risk Sparing for Advanced Cervix Carcinoma Utilizing Precision Radiotherapy Techniques. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 586-591.	2.0	31
177	Concepts for critical organ dosimetry in three-dimensional image-based breast brachytherapy. <i>Brachytherapy</i> , 2008, 7, 320-326.	0.5	17
178	Image-Guided Radiotherapy for Cervix Cancer: High-Tech External Beam Therapy Versus High-Tech Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1272-1278.	0.8	143
179	Can protons improve SBRT for lung lesions? Dosimetric considerations. <i>Radiotherapy and Oncology</i> , 2008, 88, 368-375.	0.6	54
180	Radiation dose associated with local control in advanced anal cancer: Retrospective analysis of 129 patients. <i>Radiotherapy and Oncology</i> , 2008, 87, 367-375.	0.6	42

#	ARTICLE	IF	CITATIONS
181	Consequences of random and systematic reconstruction uncertainties in 3D image based brachytherapy in cervical cancer. <i>Radiotherapy and Oncology</i> , 2008, 89, 156-163.	0.6	119
182	Abdominal cancer during early childhood: A dosimetric comparison of proton beams to standard and advanced photon radiotherapy. <i>Radiotherapy and Oncology</i> , 2008, 89, 141-149.	0.6	52
183	Inter- and intraobserver variation in HR-CTV contouring: Intercomparison of transverse and paratransverse image orientation in 3D-MRI assisted cervix cancer brachytherapy. <i>Radiotherapy and Oncology</i> , 2008, 89, 164-171.	0.6	76
184	Radiotherapy in Lymph Node-Positive Prostate Cancer Patients – A Potential Cure? , 2008, 41, 68-76.		4
185	Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 2082-2087.	7.0	28
186	3D MRI-based brachytherapy for cervical cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 351-358.	0.4	2
187	Present status and future of high-precision image guided adaptive brachytherapy for cervix carcinoma. <i>Acta Oncologica</i> , 2008, 47, 1325-1336.	1.8	105
188	3D-conformal radiotherapy for inoperable non-small-cell lung cancer - A single centre experience. <i>Radiotherapy and Oncology</i> , 2007, 41, 133.	1.7	2
189	Randomized comparison between intracoronary 125 I-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis. <i>Radiotherapy and Oncology</i> , 2007, 82, 18-23.	0.6	15
190	Accelerated partial breast irradiation with multi-catheter brachytherapy: Local control, side effects and cosmetic outcome for 274 patients. Results of the German–Austrian multi-centre trial. <i>Radiotherapy and Oncology</i> , 2007, 82, 281-286.	0.6	137
191	Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. <i>Radiotherapy and Oncology</i> , 2007, 83, 148-155.	0.6	475
192	The current place of radiation therapy in cervical cancer – Focus on image-based brachytherapy. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 420-422.	2.2	0
193	Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: Results of a prospective multicenter study of 166 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 78-83.	0.8	63
194	Uncertainties in Assessment of the Vaginal Dose for Intracavitary Brachytherapy of Cervical Cancer using a Tandem-ring Applicator. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1451-1459.	0.8	54
195	Practice Patterns of Radiotherapy in Cervical Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 485-490.	0.8	29
196	Computed Tomography Versus Magnetic Resonance Imaging-Based Contouring in Cervical Cancer Brachytherapy: Results of a Prospective Trial and Preliminary Guidelines for Standardized Contours. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 491-498.	0.8	425
197	Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 334-340.	0.8	209
198	Treatment Planning for MRI Assisted Brachytherapy of Gynecologic Malignancies Based on Total Dose Constraints. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 619-627.	0.8	79

#	ARTICLE	IF	CITATIONS
199	In Reply to Dr. Cengiz et al.. International Journal of Radiation Oncology Biology Physics, 2007, 69, 963-964.	0.8	3
200	In Reply to Dr. Dizdar et al.. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1651.	0.8	0
201	Austrian Breast Cancer Patterns-of-Care Studies PCS93 and PCS01 versus PCS85 to Identify Changes in National Practice. Strahlentherapie Und Onkologie, 2007, 183, 170-176.	2.0	5
202	Progress in Radio-Oncology VIII. Strahlentherapie Und Onkologie, 2007, 183, 1-2.	2.0	0
203	Stereotactic Photon Beam Irradiation of Uveal Melanoma: Indications and Experience at the University of Vienna since 1997. Strahlentherapie Und Onkologie, 2007, 183, 11-13.	2.0	16
204	Preliminary Results of a Comparison between High-tech External Beam and High-tech Brachytherapy for Cervix Carcinoma. Strahlentherapie Und Onkologie, 2007, 183, 19-20.	2.0	7
205	3-D conformal radiotherapy of localized prostate cancer: A subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects. Radiotherapy and Oncology, 2006, 78, 36-40.	0.6	14
206	Randomized blinded clinical trial of intracoronary brachytherapy with ⁹⁰ Sr/Y beta-radiation for the prevention of restenosis after stent implantation in native coronary arteries in diabetic patients. Radiotherapy and Oncology, 2006, 78, 60-66.	0.6	6
207	Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy and Oncology, 2006, 78, 67-77.	0.6	1,387
208	Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations. Radiotherapy and Oncology, 2006, 78, 185-193.	0.6	83
209	3D conformal HDR-brachy- and external beam therapy plus simultaneous Cisplatin for high-risk cervical cancer: Clinical experience with 3 year follow-up. Radiotherapy and Oncology, 2006, 79, 80-86.	0.6	62
210	Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies. Radiotherapy and Oncology, 2006, 80, 19-26.	0.6	85
211	Dosimetric comparison of stereotactic body radiotherapy in different respiration conditions: A modeling study. Radiotherapy and Oncology, 2006, 81, 97-104.	0.6	35
212	Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer. Radiotherapy and Oncology, 2006, 81, 269-275.	0.6	74
213	Radiation Therapy of Invasive Breast Cancer. Breast Care, 2006, 1, 396-401.	1.4	0
214	Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: Potential of MRI on delineation of target, pathoanatomic structures, and organs at risk. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1380-1388.	0.8	114
215	Optimizing LINAC-based stereotactic radiotherapy of uveal melanomas: 7 years' clinical experience. International Journal of Radiation Oncology Biology Physics, 2006, 66, S47-S52.	0.8	19
216	The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Design, application, treatment planning, and dosimetric results. International Journal of Radiation Oncology Biology Physics, 2006, 65, 624-630.	0.8	277

#	ARTICLE	IF	CITATIONS
217	The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Clinical feasibility and preliminary results. International Journal of Radiation Oncology Biology Physics, 2006, 66, 83-90.	0.8	235
218	Is mask-based stereotactic head-and-neck fixation as precise as stereotactic head fixation for precision radiotherapy?. International Journal of Radiation Oncology Biology Physics, 2006, 66, S61-S66.	0.8	19
219	3-D Conformal radiotherapy of localized prostate cancer within an Austrianâ€“German multicenter trial: a prospective study of patients' acceptance of the rectal balloon during treatment. Wiener Klinische Wochenschrift, 2006, 118, 224-229.	1.9	6
220	Ultrasound-Guided Interstitial Brachytherapy in the Treatment of Advanced Vaginal Recurrences from Cervical and Endometrial Carcinoma. Strahlentherapie Und Onkologie, 2006, 182, 86-95.	2.0	51
221	Inverse Planning â€“ a Comparative Intersystem and Interpatient Constraint Study. Strahlentherapie Und Onkologie, 2006, 182, 473-480.	2.0	23
222	Long-Term Results in Three-Dimensional Conformal Radiotherapy of Localized Prostate Cancer at Moderate Dose (66 Gy). Strahlentherapie Und Onkologie, 2006, 182, 537-542.	2.0	17
223	Endovascular Brachytherapy for Prophylaxis of Restenosis after Femoropopliteal Angioplasty: Five-year Follow-upâ€“Prospective Randomized Study. Radiology, 2006, 240, 878-884.	7.3	31
224	11C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer. Journal of Clinical Oncology, 2006, 24, 2513-2519.	1.6	114
225	Vascular Brachytherapy. , 2006, , 389-395.		0
226	Pilot study in the treatment of endometrial carcinoma with 3D imageâ€“based high-dose-rate brachytherapy using modified Heyman packing: Clinical experience and doseâ€“volume histogram analysis. International Journal of Radiation Oncology Biology Physics, 2005, 62, 468-478.	0.8	60
227	Impact of IMRT and leaf width on stereotactic body radiotherapy of liver and lung lesions. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1572-1581.	0.8	42
228	Recommendations for image-based intracavitary brachytherapy of cervix cancer: The GYN GEC ESTRO Working Group point of view: In regard to Nag et al. (Int J Radiat Oncol Biol Phys 2004;60:1160â€“1172). International Journal of Radiation Oncology Biology Physics, 2005, 62, 293-295.	0.8	34
229	Proton beam radiotherapy versus fractionated stereotactic radiotherapy for uveal melanomas: A comparative study. International Journal of Radiation Oncology Biology Physics, 2005, 63, 373-384.	0.8	65
230	Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 901-911.	0.8	306
231	In response to Dr. Narayan et al. International Journal of Radiation Oncology Biology Physics, 2005, 63, 646-647.	0.8	0
232	Comparative Treatment Planning on Localized Prostate Carcinoma. Strahlentherapie Und Onkologie, 2005, 181, 448-455.	2.0	70
233	3D-conformal radiotherapy for prevention of carotid recurrent in-stent restenosis: Initial experience. Wiener Klinische Wochenschrift, 2005, 117, 293-296.	1.9	3
234	Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wiener Klinische Wochenschrift, 2005, 117, 821-826.	1.9	13

#	ARTICLE	IF	CITATIONS
235	Endovascular Brachytherapy: Restenosis in de Novo versus Recurrent Lesions of Femoropopliteal Arteryâ€”The Vienna Experience. Radiology, 2005, 236, 338-342.	7.3	27
236	Vascular Brachytherapy with ¹⁹² Ir after Femoropopliteal Stent Implantation in High-Risk Patients: Twelve-month Follow-up Results from the Vienna-5 Trial. Radiology, 2005, 236, 343-351.	7.3	26
237	Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna-3 randomised multicenter study. Radiotherapy and Oncology, 2005, 74, 3-9.	0.6	49
238	GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiotherapy and Oncology, 2005, 74, 137-148.	0.6	186
239	Recommendations from Gynaecological (GYN) GEC-ESTRO Working Groupâ€”(I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiotherapy and Oncology, 2005, 74, 235-245.	0.6	1,315
240	In-vivo dosimetry for gynaecological brachytherapy: Physical and clinical considerations. Radiotherapy and Oncology, 2005, 77, 310-317.	0.6	63
241	Salvage Therapy of Progressive and Recurrent Hodgkinâ€™s Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group. Journal of Clinical Oncology, 2005, 23, 6181-6189.	1.6	107
242	Basic treatment planning parameters for a ⁹⁰ Sr/ ⁹⁰ Y source train used in endovascular brachytherapy. Zeitschrift Fur Medizinische Physik, 2004, 14, 159-167.	1.5	0
243	Endovascular Brachytherapy: Effect on Acute Inflammatory Response after Percutaneous Femoropopliteal Arterial Interventions. Radiology, 2004, 230, 556-560.	7.3	5
244	Automatic real-time surveillance of eye position and gating for stereotactic radiotherapy of uveal melanoma. Medical Physics, 2004, 31, 3521-3527.	3.0	37
245	Estimation of doses to personnel and patients during endovascular brachytherapy applications. Radiation Protection Dosimetry, 2004, 108, 237-245.	0.8	3
246	Increased Dosage during Intracoronary Irradiation Due to Overlapped Source Stepping Shows No Long-Term Adverse Changes in Vessel Morphology. Journal of Interventional Cardiology, 2004, 17, 143-149.	1.2	0
247	Interstitial brachytherapy alone after breast conserving surgery: Interim results of a German-Austrian multicenter phase II trial. Brachytherapy, 2004, 3, 115-119.	0.5	55
248	Accelerated Partial Breast Irradiation with Iridium-192 Multicatheter PDR/HDR Brachytherapy. Strahlentherapie Und Onkologie, 2004, 180, 642-649.	2.0	57
249	Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 147-154.	0.8	183
250	Treatment parameters for beta and gamma devices in peripheral endovascular brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1652-1659.	0.8	3
251	Radiobiological rationale and patient selection for high-LET radiation in cancer therapy. Radiotherapy and Oncology, 2004, 73, S1-S14.	0.6	22
252	Epidemiological aspects of hadron therapy: A prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO). Radiotherapy and Oncology, 2004, 73, S24-S28.	0.6	17

#	ARTICLE	IF	CITATIONS
253	General principles for prescribing, recording and reporting a therapeutic irradiation. Radiotherapy and Oncology, 2004, 73, S57-S61.	0.6	10
254	Clinical quality assurance for endovascular brachytherapy devices. Radiotherapy and Oncology, 2004, 71, 91-98.	0.6	10
255	Effects of geometric distortion in 0.2T MRI on radiotherapy treatment planning of prostate cancer. Radiotherapy and Oncology, 2004, 71, 55-64.	0.6	55
256	Patterns of care in radiotherapy of breast cancer in Austria 1985: data acquisition and comparison with data of US-PCS 1983. Radiotherapy and Oncology, 2004, 72, 45-51.	0.6	3
257	Acute Side Effects during 3-D-Planned Conformal Radiotherapy of Prostate Cancer. Strahlentherapie Und Onkologie, 2003, 179, 320-327.	2.0	46
258	Oxygenation Status of Cervical Carcinomas Before and During Spinal Anesthesia for Application of Brachytherapy. Strahlentherapie Und Onkologie, 2003, 179, 633-640.	2.0	16
259	Impact of a micromultileaf collimator on stereotactic radiotherapy of uveal melanoma. International Journal of Radiation Oncology Biology Physics, 2003, 55, 881-891.	0.8	48
260	Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. International Journal of Radiation Oncology Biology Physics, 2003, 56, 644-652.	0.8	29
261	High-dose-rate (HDR) brachytherapy with or without external beam radiotherapy in the treatment of primary vaginal carcinoma: Long-term results and side effects. International Journal of Radiation Oncology Biology Physics, 2003, 56, 950-957.	0.8	70
262	A noninvasive eye fixation and computer-aided eye monitoring system for linear accelerator-based stereotactic radiotherapy of uveal melanoma. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1128-1136.	0.8	37
263	LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiotherapy and Oncology, 2003, 67, 199-206.	0.6	99
264	The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial. Radiotherapy and Oncology, 2003, 68, 51-59.	0.6	102
265	Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point. Radiotherapy and Oncology, 2003, 68, 269-276.	0.6	151
266	Normalized sensitometric curves for the verification of hybrid IMRT treatment plans with multiple energies. Medical Physics, 2003, 30, 1142-1150.	3.0	32
267	Neoadjuvant Hormonal Treatment and Radiotherapy for Prostate Cancer. Oncology, 2003, 65, 29-33.	1.9	52
268	Locally Recurrent Breast Cancer: Pulse Dose Rate Brachytherapy for Repeat Irradiation Following Lumpectomy-A Second Chance to Preserve the Breast. Radiology, 2002, 225, 713-718.	7.3	102
269	TP53 Genotype but Not p53 Immunohistochemical Result Predicts Response to Preoperative Short-Term Radiotherapy in Rectal Cancer. Annals of Surgery, 2002, 235, 493-498.	4.2	78
270	Planning Target Volume and Dose Prescription in Definitive Radiotherapy for Prostate Cancer with Favourable Prognostic Factors. , 2002, 36, 1-9.		0

#	ARTICLE	IF	CITATIONS
271	Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the Germanâ€Austrian pediatric multicenter trial DAL-HD-90. Radiotherapy and Oncology, 2002, 62, 191-200.	0.6	40
272	Possible impact of iridium-192 source centering on restenosis rate after femoro-popliteal angioplasty and endovascular brachytherapy in Vienna-2 study. Radiotherapy and Oncology, 2002, 63, 97-102.	0.6	16
273	Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiotherapy and Oncology, 2002, 63, 47-58.	0.6	52
274	Determination and application of the reference isodose length (RIL) for commercial endovascular brachytherapy devices. Radiotherapy and Oncology, 2002, 64, 309-315.	0.6	25
275	Vascular morphometric changes after radioactivestent implantation: a dose-response analysis. Journal of the American College of Cardiology, 2002, 39, 400-407.	2.8	4
276	Geographical miss during intracoronary irradiation: impact on restenosis and determination of required safety margin length. Journal of the American College of Cardiology, 2002, 40, 1225-1231.	2.8	23
277	Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Letters, 2002, 179, 197-203.	7.2	48
278	Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. International Journal of Cancer, 2002, 102, 237-243.	5.1	80
279	Interobserver Comparison of CT and MRI-Based Prostate Apex Definition. Strahlentherapie Und Onkologie, 2002, 178, 263-268.	2.0	41
280	Biochemical Response after 3-D Conformal Radiotherapy of Localized Prostate Cancer to a Total Dose of 66 Gy. Strahlentherapie Und Onkologie, 2002, 178, 542-547.	2.0	12
281	Present Status of Endovascular Brachytherapy in Peripheral Arteries. Herz, 2002, 27, 56-61.	1.1	8
282	The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2002, 52, 91-100.	0.8	158
283	Katheterbasierte ^{132}I -HDR-Brachytherapie der peripheren GefäÙe. , 2002, , 233-245.		0
284	Doseâ€volume histograms based on serial intravascular ultrasound: a calculation model for radioactive stents. Radiotherapy and Oncology, 2001, 59, 329-337.	0.6	3
285	Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy. Radiotherapy and Oncology, 2001, 58, 11-18.	0.6	81
286	Quality control in interstitial brachytherapy of the breast using pulsed dose rate: treatment planning and dose delivery with an Ir-192 afterloading system. Radiotherapy and Oncology, 2001, 58, 43-51.	0.6	43
287	Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects. Radiotherapy and Oncology, 2001, 58, 53-62.	0.6	133
288	Recommendations of the EVA GEC ESTRO Working Group: prescribing, recording, and reporting in endovascular brachytherapy. Quality assurance, equipment, personnel and education. Radiotherapy and Oncology, 2001, 59, 339-360.	0.6	67

#	ARTICLE	IF	CITATIONS
289	Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. <i>Radiotherapy and Oncology</i> , 2001, 59, 65-70.	0.6	151
290	Erratum to : "Recommendations of the EVA GEC ESTRO Working Group: prescribing, recording, and reporting in endovascular brachytherapy. Quality assurance, equipment, personnel and education" [Radiother. Oncol. 59 (2001) 339-360]. <i>Radiotherapy and Oncology</i> , 2001, 60, 337-338.	0.6	6
291	A linac-based stereotactic irradiation technique of uveal melanoma. <i>Radiotherapy and Oncology</i> , 2001, 61, 49-56.	0.6	58
292	Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2001, 80, 355-355.	2.8	22
293	Aspects of MR Image Distortions in Radiotherapy Treatment Planning. <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 59-73.	2.0	118
294	Radiation therapy in the treatment of endometrial stromal sarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 739-748.	0.8	76
295	Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 665-671.	0.8	32
296	Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2001, 80, 355-360.	2.8	24
297	Endovascular Brachytherapy for Prophylaxis against Restenosis after Long-Segment Femoropopliteal Placement of Stents: Initial Results. <i>Radiology</i> , 2001, 220, 724-729.	7.3	47
298	Effect of distortions and asymmetry in MR images on radiotherapeutic treatment planning. , 2000, 90, 46-50.		13
299	Quality of life changes during conformal radiation therapy for prostate carcinoma. <i>Cancer</i> , 2000, 89, 1322-1328.	4.1	83
300	Intraarterial 192Ir high-dose-rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna-2-trial radiotherapy parameters and risk factors analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 923-931.	0.8	60
301	Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. <i>Sarcoma</i> , 2000, 4, 151-160.	1.3	89
302	Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. <i>Radiotherapy and Oncology</i> , 2000, 55, 135-144.	0.6	110
303	Quality assurance in preoperative radiotherapy of rectal cancer: evaluation of a pre-trial dummy-run. <i>Radiotherapy and Oncology</i> , 2000, 56, 341-347.	0.6	21
304	Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. <i>Radiotherapy and Oncology</i> , 2000, 54, 11-19.	0.6	135
305	High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90. <i>Journal of Clinical Oncology</i> , 1999, 17, 3736-3744.	1.6	227
306	Portal imaging based definition of the planning target volume during pelvic irradiation for gynecological malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 227-232.	0.8	17

#	ARTICLE	IF	CITATIONS
307	Results of Primary and Adjuvant Radiotherapy in the Treatment of Mixed Malignant Tumors of the Corpus Uteri. Gynecologic Oncology, 1999, 73, 389-395.	1.4	33
308	Results of fast neutron therapy of adenoid cystic carcinoma of the salivary glands. Strahlentherapie Und Onkologie, 1999, 175, 65-68.	2.0	19
309	Fractionated stereotactic radiotherapy with linear accelerator for uveal melanoma – Preliminary vienna results. Strahlentherapie Und Onkologie, 1999, 175, 74-75.	2.0	21
310	Treatment results of fast neutron irradiation in soft tissue sarcomas. Strahlentherapie Und Onkologie, 1999, 175, 76-78.	2.0	12
311	Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: Early results. Strahlentherapie Und Onkologie, 1999, 175, 84-86.	2.0	9
312	A challenge for high-precision radiation therapy: The case for hadrons. Strahlentherapie Und Onkologie, 1999, 175, 122-128.	2.0	8
313	Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiotherapy and Oncology, 1999, 50, 185-190.	0.6	81
314	External audit on the clinical practice and medical decision-making at the departments of radiotherapy in Budapest and Vienna. Radiotherapy and Oncology, 1999, 51, 87-94.	0.6	13
315	The benefit of Beam's eye view based 3D treatment planning for cervical cancer. Radiotherapy and Oncology, 1999, 51, 71-78.	0.6	55
316	Intratumoral pO ₂ -measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiotherapy and Oncology, 1999, 53, 99-104.	0.6	213
317	Abdominal Irradiation in Unilateral Nephroblastoma and its Impact on Local Control and Survival. International Journal of Radiation Oncology Biology Physics, 1998, 40, 163-169.	0.8	10
318	Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer, 1998, 83, 1972-1979.	4.1	68
319	Treatment of children with relapsed soft tissue sarcoma: Report of the German CESS/CWS REZ 91 Trial. , 1998, 30, 269-275.		60
320	Reproducibility of irregular radiation fields for malignant lymphoma. Strahlentherapie Und Onkologie, 1998, 174, 529-33.	2.0	2
321	Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstetrica Et Gynecologica Scandinavica, 1998, 77, 1008-1012.	2.8	17
322	Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstetrica Et Gynecologica Scandinavica, 1998, 77, 1008-1012.	2.8	42
323	Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: Results of 12 years of experience with 280 patients. International Journal of Radiation Oncology Biology Physics, 1997, 37, 359-365.	0.8	79
324	Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas. , 1997, 80, 2273-2284.		63

#	ARTICLE	IF	CITATIONS
325	Brachytherapy in the Combined Modality Treatment of Pediatric Malignancies. Principles and Preliminary Experience with Treatment of Soft Tissue Sarcoma (Recurrence) and Ewing's Sarcoma. Klinische Padiatrie, 1995, 207, 164-173.	0.6	30
326	Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9/GPOH. Radiotherapy and Oncology, 1994, 31, 222-228.	0.6	40
327	Sagittal and coronal planes from MRI for treatment planning in tumors of brain, head and neck: MRI assisted simulation. Radiotherapy and Oncology, 1992, 23, 127-130.	0.6	35
328	Digital subtraction angiography (IV DSA) in treatment planning of subdiaphragmatic Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1989, 17, 389-396.	0.8	5
329	Paraneoplastic subacute cerebellar degeneration in Hodgkin's disease. Clinical Neurology and Neurosurgery, 1989, 91, 329-335.	1.4	26
330	Results of high dose 106-ruthenium irradiation of choroidal melanomas. International Journal of Radiation Oncology Biology Physics, 1986, 12, 1749-1755.	0.8	34